[go: up one dir, main page]

PL3096759T3 - Preparaty pridopidyny o zmodyfikowanym uwalnianiu - Google Patents

Preparaty pridopidyny o zmodyfikowanym uwalnianiu

Info

Publication number
PL3096759T3
PL3096759T3 PL15740303T PL15740303T PL3096759T3 PL 3096759 T3 PL3096759 T3 PL 3096759T3 PL 15740303 T PL15740303 T PL 15740303T PL 15740303 T PL15740303 T PL 15740303T PL 3096759 T3 PL3096759 T3 PL 3096759T3
Authority
PL
Poland
Prior art keywords
pridopidine
release formulations
modified release
modified
formulations
Prior art date
Application number
PL15740303T
Other languages
English (en)
Inventor
Daniella Licht
Ioana Lovinger
Laura Yehudit Guilatt
Merav Bassan
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53543863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3096759(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3096759T3 publication Critical patent/PL3096759T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
PL15740303T 2014-01-22 2015-01-21 Preparaty pridopidyny o zmodyfikowanym uwalnianiu PL3096759T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461930358P 2014-01-22 2014-01-22
US201462050626P 2014-09-15 2014-09-15
PCT/US2015/012248 WO2015112601A1 (en) 2014-01-22 2015-01-21 Modified release formulations of pridopidine
EP15740303.1A EP3096759B1 (en) 2014-01-22 2015-01-21 Modified release formulations of pridopidine

Publications (1)

Publication Number Publication Date
PL3096759T3 true PL3096759T3 (pl) 2022-06-13

Family

ID=53543863

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15740303T PL3096759T3 (pl) 2014-01-22 2015-01-21 Preparaty pridopidyny o zmodyfikowanym uwalnianiu

Country Status (20)

Country Link
US (3) US20150202302A1 (pl)
EP (2) EP3096759B1 (pl)
JP (2) JP6949487B2 (pl)
KR (1) KR102479759B1 (pl)
CN (1) CN106170287A (pl)
AU (1) AU2015209411A1 (pl)
CA (1) CA2937243C (pl)
CL (1) CL2016001874A1 (pl)
DK (1) DK3096759T3 (pl)
EA (1) EA201691454A1 (pl)
ES (1) ES2911800T3 (pl)
HU (1) HUE058288T2 (pl)
IL (2) IL246598B (pl)
MX (1) MX377576B (pl)
PE (1) PE20161220A1 (pl)
PL (1) PL3096759T3 (pl)
TW (1) TW201605446A (pl)
UA (1) UA122053C2 (pl)
UY (1) UY35962A (pl)
WO (1) WO2015112601A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017015615A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
CA3015512C (en) 2016-02-24 2024-01-16 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
CA3035092C (en) 2016-08-24 2022-05-31 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating functional decline
CA3035099C (en) * 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
DK4005570T3 (da) * 2016-09-16 2024-08-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse behandling af retts syndroe
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
AU2018210145B2 (en) 2017-01-20 2023-06-29 Agency For Science, Technology And Research Use of pridopidine for the treatment of fragile X syndrome
BR112020003119A2 (pt) 2017-08-14 2020-10-13 Prilenia Neurotherapeutics Ltd. método de tratamento de esclerose lateral amiotrófica com pridopidina
EP3675830A1 (en) * 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
KR20200056071A (ko) 2018-11-14 2020-05-22 한화토탈 주식회사 내열성, 강성 및 용융 강도가 우수한 폴리올레핀 수지 조성물
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4020983B2 (ja) * 1995-07-07 2007-12-12 帝國製薬株式会社 持続性製剤およびその製法
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
RU2277416C2 (ru) * 2000-03-21 2006-06-10 Ниппон Синяку Ко., Лтд. Препараты для перорального введения с замедленным высвобождением
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
UY34503A (es) * 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
WO2014205229A1 (en) * 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.

Also Published As

Publication number Publication date
IL280485B2 (en) 2023-05-01
TW201605446A (zh) 2016-02-16
JP6949487B2 (ja) 2021-10-13
CN106170287A (zh) 2016-11-30
MX2016009427A (es) 2016-12-08
MX377576B (es) 2025-03-04
EP3096759B1 (en) 2022-04-06
IL246598A0 (en) 2016-08-31
JP2017503823A (ja) 2017-02-02
WO2015112601A1 (en) 2015-07-30
KR20160125385A (ko) 2016-10-31
HUE058288T2 (hu) 2022-07-28
CA2937243C (en) 2023-07-18
ES2911800T3 (es) 2022-05-20
EA201691454A1 (ru) 2017-01-30
UY35962A (es) 2015-08-31
CA2937243A1 (en) 2015-07-30
JP7266298B2 (ja) 2023-04-28
KR102479759B1 (ko) 2022-12-21
PE20161220A1 (es) 2016-11-23
EP3096759A4 (en) 2017-08-02
EP3096759A1 (en) 2016-11-30
US20240041855A1 (en) 2024-02-08
IL280485A (en) 2021-03-01
IL280485B1 (en) 2023-01-01
AU2015209411A1 (en) 2016-09-01
US20150202302A1 (en) 2015-07-23
IL246598B (en) 2021-01-31
EP4049657A1 (en) 2022-08-31
US20190209542A1 (en) 2019-07-11
UA122053C2 (uk) 2020-09-10
CL2016001874A1 (es) 2017-05-12
DK3096759T3 (da) 2022-05-09
JP2020023518A (ja) 2020-02-13

Similar Documents

Publication Publication Date Title
IL280485A (en) Sustained-release pridopidine preparations
IL250511A0 (en) Crystalline forms of ibrutinib
PL3137060T5 (pl) Kompozycje zawiesinowe o przedłużonym uwalnianiu
PL3099381T3 (pl) Kompozycje środków zapachowych o przedłużonym uwalnianiu
PT3102555T (pt) Composições de compostos e seus usos
GB201404139D0 (en) Sustained release buprenorphine solution formulations
IL252062A0 (en) Transdermal compositions
PT3474822T (pt) Formulações de brincidofovir
SI3524234T1 (sl) Trdne oblike sofosbuvira
GB201419091D0 (en) Formulations
IL248223B (en) Compositions of vaccine
PL3223837T3 (pl) Lactobacillus do zastosowania jako probiotyk
GB201419261D0 (en) Formulations
IL246979A0 (en) Crystalline forms of sofosbuvir
SG11201803156TA (en) Sustained release formulations of local anesthetics
PL3142641T3 (pl) Preparaty do leczenia nadczynności tarczycy
IL247828A0 (en) Progesterone compounds
IL246569A0 (en) Solid forms of tenofovir
IL249130B (en) Preparation of piperidine-4-carbothioamide
TWI561205B (en) Quick release structure of electrosurgical unit
HK1228789A1 (en) Modified release formulations of pridopidine
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201412359D0 (en) Composition of objects
GB201412089D0 (en) Composition of objects
GB201418410D0 (en) use of compositions of matter